This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.Chronic lymphocytic leukemia is rarely curative disease. Novel treatments are needed. Like many other malignancies, tumor suppressor genes may be silenced by DNA methylation in chronic lymphocytic leukemia. Vidaza, a DNA methylation inhibitor, is already approved for treatment of patients with myelodysplastic syndrome. This study proposes to study if Vidaza is an effective DNA methylation inhibitor in patients with chronic lymphocytic leukemia.
Showing the most recent 10 out of 535 publications